David Ellis

Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry

S. Lade, E. Wood, M. Gandhi, 2022, BMC Medical Research Methodology.

Phase II study of autologous stem cell transplant using busulfan–melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma

H. Prince, A. Schwarer, D. Gill, 2010, Leukemia & lymphoma.

A phase III randomized trial of high‐dose CEOP + filgrastim versus standard‐dose CEOP in patients with non‐Hodgkin lymphoma: 10‐year follow‐up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial

P. Marlton, J. Matthews, P. Browett, 2014, American journal of hematology.

A phase III randomized trial of high‐dose CEOP + filgrastim versus standard‐dose CEOP in patients with non‐Hodgkin lymphoma: 10‐year follow‐up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial

P. Marlton, J. Matthews, P. Browett, 2014, American journal of hematology.